Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2024-202348

Published: 2024

Journal Articles

CAR T-cell therapy in multiple myeloma: mission accomplished?

Leo Rasche, Michael Hudecek, Hermann Einsele

Blood (2024) 143 (4): 305–310.

https://doi.org/10.1182/blood.2023021221

Published: 2024

Journal Articles

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Maximilian J Steinhardt, Patrick Eiring, Cornelia Vogt, Umair Munawar, Seungbin Han, Larissa Haertle, Silvia Nerreter, Eva Teufel, Julia Mersi, Xiang Zhou, Michael Hudecek, Joaquin Martinez-Lopez, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, Markus Sauer, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2023-189741

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

Belén Sierro-Martínez, Virginia Escamilla Gomez, Laura Perez-Ortega, Beatriz Guijarro-Albaladejo, Paola Hernández-Díaz, María de la Rosa-Garrido, Maribel Lara-Chica, Juan Luis Reguera, Luzalba Sanoja Flores, Blanca Arribas-Arribas, Miguel-Ángel Montiel-Aguilera, Gloria Carmona, Maria-Jose Robles, Teresa Caballero, Javier Briones, Hermann Einsele, Michael Hudecek, Jose A. Pérez-Simón, Estefania Garcia-Guerrero

Blood (2023) 142 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2023-186095

Published: 2023

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Blood (2022) 140 (Supplement 1): 4230–4231.

https://doi.org/10.1182/blood-2022-169255

Published: 2022

Journal Articles

Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM

Blood (2022) 140 (Supplement 1): 4226–4227.

https://doi.org/10.1182/blood-2022-168702

Published: 2022

Journal Articles

Highjacking myeloma’s niche with beefed-up CAR-Ts

Michael Hudecek, Hermann Einsele

Blood (2022) 139 (26): 3671–3672.

https://doi.org/10.1182/blood.2022015707

Published: 2022

Journal Articles

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Verbruggen, Ana Yeguas, María Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek

Blood (2021) 138 (19): 1830–1842.

https://doi.org/10.1182/blood.2020009192

Published: 2021

Includes: Supplemental data

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency

Tobias Bexte, Lacramioara Botezatu, Csaba Miskey, Julia Campe, Lisa Marie Reindl, Veronika Gebel, Winfried S Wels, Michael Hudecek, Zoltan Ivics, Evelyn Ullrich

Blood (2021) 138 (Supplement 1): 2797.

https://doi.org/10.1182/blood-2021-153999

Published: 2021

Journal Articles

What is the future of immunotherapy in multiple myeloma?

Leo Rasche, Michael Hudecek, Hermann Einsele

Blood (2020) 136 (22): 2491–2497.

https://doi.org/10.1182/blood.2019004176

Published: 2020

Journal Articles

ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells

Estefania Garcia-Guerrero, PhD, Luis Gerardo Rodríguez-Lobato, Sophia Danhof, MD, Belén Sierro-Martínez, Ralph Goetz, Markus Sauer, Jose A. Perez-Simon, MD PhD, Hermann Einsele, MD, Michael Hudecek, MD, Sabrina Prommersbe

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142572

Published: 2020

Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1277.

https://doi.org/10.1182/blood-2019-129762

Published: 2019

Journal Articles

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Margot J. Pont, Tyler Hill, Gabriel O. Cole, Joe J. Abbott, Jessica Kelliher, Alexander I. Salter, Michael Hudecek, Melissa L. Comstock, Anusha Rajan, Bharvin K. R. Patel, Jenna M. Voutsinas, Qian Wu, Lingfeng Liu, Andrew J. Cowan, Brent L. Wood, Damian J. Green, Stanley R. Riddell

Blood (2019) 134 (19): 1585–1597.

https://doi.org/10.1182/blood.2019000050

Published: 2019

Includes: Supplemental data

Journal Articles

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Matteo Giovanni Carrabba, MD, Monica Casucci, PhD, Michael Hudecek, MD, Concetta Quintarelli, PhD, Javier Briones, MD, Roman Hajek, MD PhD, Jorge Sierra, MD, Franco Locatelli, Hermann Einsele, MD PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Catia Traversari, PhD

Blood (2018) 132 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2018-99-117974

Published: 2018

Journal Articles

A Novel Pharmacologic 'Remote Control' to Steer CAR-T Cell Function In Vivo

Katrin Mestermann, Julian Rydzek, Frenz Silke, Thomas Nerreter, Mades Andreas, Hermann Einsele, MD, Michael Hudecek, MD

Blood (2018) 132 (Supplement 1): 2055.

https://doi.org/10.1182/blood-2018-99-118626

Published: 2018

Journal Articles

FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells

Hardikkumar Jetani, Irene García-Cadenas, Thomas Nerreter, Ralph Goetz, Jorge Sierra, MD, Halvard Bonig, MD, Markus Sauer, Hermann Einsele, MD, Michael Hudecek, MD

Blood (2018) 132 (Supplement 1): 903.

https://doi.org/10.1182/blood-2018-99-118171

Published: 2018

NARROW

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

CAR T-cell therapy in multiple myeloma: mission accomplished?

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM

Highjacking myeloma’s niche with beefed-up CAR-Ts

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency

What is the future of immunotherapy in multiple myeloma?

ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

A Novel Pharmacologic 'Remote Control' to Steer CAR-T Cell Function In Vivo

FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only